- 03-06-2011, 03:47 PM
- 03-06-2011, 05:43 PM
you mean methyl hydroxy nandrolone? It's been banned for a while, but being that it is very hard to find, it must be good.OLYMPUS UK REP
30% OFF OLYMPUS UK USING JBUK30 GET SWOLE!
- 03-06-2011, 06:01 PM
03-06-2011, 06:05 PM
I must not be looking hard enough. good to know though.
OLYMPUS UK REP
30% OFF OLYMPUS UK USING JBUK30 GET SWOLE!
03-06-2011, 06:32 PM
MHN looks great on paper- but didnt work to well in real world i have a write up hold on
not the official one
Standard Methyltestosterone (oral)
Chemical Name 4-Hydroxy-17alpha-methyl hydroxyestra4-ene-3-one
Estrogenic Activity none
Progestational Activity none
Methylhydroxynandrolone, or MOHN for short, is a potent derivative of nandrolone. This agent is orally active and non-aromatizable, with a profile somewhat simi-Iar to that of Winstrol or Anavar -primarily anabolic, with no discernable estrogenic activity. According to early assay results, methylhydroxynandrolone is 13 times more anabolic than methyltestosterone, with approximately 3 times greater androgenicity. Although animal assay data doesn't translate perfectly to humans, it remains clear that MOHN is considerably stronger on a milligram for milligram basis than the common prescription steroids. MOHN is also a bit more androgenic than the assay data conveys, and behaves slightly more like trenbolone than nandrolone in this regard. Its 4-hydroxyl group, a modification that prevents its 5-alpha reduction in humans to weaker "dihydro" metabolites in the skin, scalp and prostate, intensifies the relative androgenicity of this AAS. Athletes favor it for lean gains in muscle mass, strength, and performance, with minimal side effects.
Methylhydroxynandrolone was first described in 1964,
developed during a series of investigations that looked at the effects of 4-hydroxylation on various nandrolone compounds.634 Being that 4-hydroxylation inhibits 5-alpha reduction, nandrolone derivatives with this alteration tend to be more androgenic. They are, therefore, less likely to cause side effects relating to low libido and reduced androgenicity, common with injectable nandrolone esters. Although early results showed that methylhydroxynandrolone was both effective and retained a favorable ratio of anabolic to androgenic effect, it was ultimately never developed into a medicine. Only MOHN's non-methylated cousin, oxabolone (as oxabolone cypionate), had reached the stage of prescription drug product. For approximately forty years after its synthesis, little mention was made of methylhydroxynandrolone in
the medical literature. For all intents and purposes, it was a dead and forgotten anabolic AAS.
MOHN suddenly reemerged in 2004, when it was introduced as a "nutritional product" on the U.S. supplement market. It was being sold OTC, without the restrictions of a synthetic anabolic AAS. This was due primarily to the fact that it was never regulated as a drug in the U.S., and barring a direct listing in the 1991 Anabolic AAS Control Act, could not be covered by it. Its legality as a supplement may have been questionable, but that was a matter for the FDA to handle, not the DEA (Drug Enforcement Agency). MOHN has since been included in the most recent expansion of U.S. anabolic AAS laws, however, and formally became a controlled anabolic AAS on January 20,2005. Possession of this agent after this date carries all the same legal risks and consequences as other popular and illegal steroids according to Federal law. Due to the fact that it is not a prescription drug, this law effectively marked the commercial end of methylhydroxynandrolone products.
Methylhydroxynandrolone is not available as a commercial agent. When sold as a nutritional supplement, it generally
/ contained 3mg of AAS per tablet.
Methylhydroxynandrolone is a modified form of nandrolone. It differs by: 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the introduction of a hydroxyl group at carbon 4, which inhibits aromatization, progestational activity, and 5-alpha reduction, and reduces relative AAS androgenicity.
Side Effects (Estrogenic):
Methylhydroxynandrolone is not aromatized by the body, and is not measurably estrogenic. Estrogenic side effects
UII IU UIIJ II U , UN.
such as increased water retention, fat gain, and gynecomastia are not likely to occur with use. The nonestrogenic nature of methylhydroxynandrolone makes this agent favorable during cutting or lean mass phases of training, when muscle definition is favored over raw bulk gains.
Side Effects (Androgenic):
Although classified as an anabolic AAS, androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize methylhydroxynandrolone, so its relative androgenicity is not affected by finasteride or dutasteride.
Side Effects (Hepatotoxicity):
Methylhydroxynandrolone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. e17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances Iifethreatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.
Side Effects (Cardiovascular):
Its time to play the game
04-29-2010 07:35 PM #2
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic AAS on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of AAS (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Although not studied in humans, the high relative potency, oral route, and non-aromatizable nature of methylhydroxynandrolone suggest that this agent is extremely prone to negatively altering lipid values and increasing atherogenic risk. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular stra.in it is advised tc maintain an active cardiovascular exercise program anc minimize the intake of saturated fats, cholesterol, anc simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per ' day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is · also recommended.
Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to AAS abuse, necessitating medical intervention.
The above side effects are not inclusive. For more detailed discussion ofpotential side effects, see the AAS Side Effects section ofthis book.
Studies have shown that taking an oral anabolic AAS with food may decrease its bioavailability.635 This is caused by the fat-soluble nature of AAS hormones, which can allow some of the drug to dissolve with undigested dietary fat, reducing its absorption from the gastrointestinal tract. For maximum utilization, this AAS should be taken on an empty stomach.
Methylhydroxynandrolone was never approved for use in humans. Prescribing guidelines are unavailable. Effective oral daily doses for physique-or performance-enhancing purposes fall in the range of 2-10 mg. In an effort to reduce liver strain, it is usually recommended to limit drugI duration to no longer than 6-8 weeks, after which point J break is taken from all c-17 alkylated steroids. At this level MOHN should provide very solid gains in lean muscle mass and strength, without water retention or increased fat deposition. MOHN is not thought of as a bulking drud itself,although is very versatile for stacking,and mixes wei with many other anabolics depending on the individuJ goals of the user.
Methylhydroxynandrolone was never approved for use in
humans. Prescribing guidelines are unavailable. The high . anabolic to androgenic ratio of ! methylhydroxynandrolone makes use possible without
significant virilization, but would likely require small doses (1-3mg per day) and respecting a very periodic use schedule (4 weeks or less).
I Methylhydroxynandrolone is not available as a prescription agent at this time, in any part of the world. Since this agent was manufactured as a nutritional supplement for a brief period of time before the 2004 amendment to the Anabolic AAS Act went into effect, there may be some leftover drug in circulation.
03-06-2011, 06:34 PM
03-06-2011, 07:56 PM
03-06-2011, 09:10 PM
there is still some on the black market from a trusted lab- i have used this labs dianabol with great success